Alkermes plc Share Price Today: Live Updates & Key Insights

Alkermes plc share price today is $28.34, up -0.88%. The stock opened at $28.5 against the previous close of $28.4, with an intraday high of $28.87 and low of $27.96.

Alkermes plc Share Price Chart

Alkermes plc

us-stock
To Invest in {{usstockname}}
us-stock

Alkermes plc Share Price Performance

$28.34 -0.0088(-0.88%) ALKS at 23 Mar 2026 11:57 AM Drug Manufacturers - Specialty & Generic
Lowest Today 27.96
Highest Today 28.87
Today’s Open 28.5
Prev. Close 28.4
52 Week High 36.32
52 Week Low 25.17
Day’s Range: Low 27.96 High 28.87
52-Week Range: Low 25.17 High 36.32
1 day return -
1 Week return +0.53
1 month return -12.46
3 month return -1.6
6 month return +1.95
1 year return -19.01
3 year return +9.14
5 year return +38.92
10 year return -

Alkermes plc Institutional Holdings

BlackRock Inc 16.78

Vanguard Group Inc 10.81

T. Rowe Price Associates, Inc. 6.14

Baker Bros Advisors LP 6.01

iShares Core S&P Small-Cap ETF 6.00

State Street Corp 5.12

JPMorgan Chase & Co 4.71

Renaissance Technologies Corp 4.00

American Century Companies Inc 3.57

Vanguard Total Stock Mkt Idx Inv 3.15

Avantis US Small Cap Value ETF 2.71

Dimensional Fund Advisors, Inc. 2.65

Geode Capital Management, LLC 2.45

iShares Russell 2000 ETF 2.37

Vanguard Small Cap Index 2.24

T. Rowe Price US Mid-Cap Value Equity 2.24

COMMODORE CAPITAL LP 2.13

State Street® SPDR® S&P® Biotech ETF 2.04

Wellington Management Company LLP 1.81

T. Rowe Price Mid-Cap Value 1.67

First Trust NYSE Arca Biotech ETF 1.65

PRIMECAP Management Company 1.54

Nuveen, LLC 1.46

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D 1.36

Charles Schwab Investment Management Inc 1.29

JPM US Mid Cap Growth-Composite 1.26

JPMorgan Mid Cap Growth I 1.26

Vanguard Small Cap Growth Index Inv 1.25

The Goldman Sachs Group Inc 1.20

NORGES BANK 1.17

Loomis, Sayles & Company LP 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.07

Northern Trust Corp 1.06

Vanguard Capital Opportunity Inv 1.04

RTW INVESTMENTS, LLC 1.00

Fidelity Small Cap Index 0.95

State Street SPDR Port S&P 600 Sm CpETF 0.92

iShares S&P Small-Cap 600 Growth ETF 0.85

iShares Biotechnology ETF 0.72

Vanguard Tax-Managed Small Cap Adm 0.65

Alkermes plc Market Status

Strong Buy: 8

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

Alkermes plc Fundamentals

Market Cap 4691.20 M

PB Ratio 2.5786

PE Ratio 19.8239

Enterprise Value 4172.98 M

Total Assets 2530.26 M

Volume 4918306

Alkermes plc Company Financials

Annual Revenue FY25:1475899000 1475.9M, FY24:1557632000 1557.6M, FY23:1590604000 1590.6M, FY22:1111795000 1111.8M, FY21:1173751000 1173.8M

Annual Profit FY25:1273842000 1273.8M, FY24:1312301000 1312.3M, FY23:1353696000 1353.7M, FY22:893687000 893.7M, FY21:569838000 569.8M

Annual Net worth FY25:241664000 241.7M, FY24:367070000 367.1M, FY23:214724000 214.7M, FY22:-158267000 -158.3M, FY21:-48169000 -48.2M

Quarterly Revenue Q4/2025:384547000 384.5M, Q3/2025:394185000 394.2M, Q2/2025:390657000 390.7M, Q1/2025:306510000 306.5M, Q4/2024:429986000 430.0M

Quarterly Profit Q4/2025:332738000 332.7M, Q3/2025:342594000 342.6M, Q2/2025:341197000 341.2M, Q1/2025:257313000 257.3M, Q4/2024:367870000 367.9M

Quarterly Net worth Q4/2025:49341000 49.3M, Q3/2025:82761000 82.8M, Q2/2025:87098000 87.1M, Q1/2025:22464000 22.5M, Q4/2024:146503000 146.5M

About Alkermes plc & investment objective

Company Information Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Organisation Drug Manufacturers - Specialty & Generic

Employees 2050

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Richard F. Pops

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Alkermes plc FAQs

What is the share price of Alkermes plc today?

The current share price of Alkermes plc is $28.34.

Can I buy Alkermes plc shares in India?

Yes, Indian investors can buy Alkermes plc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Alkermes plc shares in India?

You can easily invest in Alkermes plc shares from India by:

Can I buy fractional shares of Alkermes plc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Alkermes plc?

Alkermes plc has a market cap of $4691.20 M.

In which sector does Alkermes plc belong?

Alkermes plc operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Alkermes plc stocks?

To invest, you typically need:

What is the PE and PB ratio of Alkermes plc?

The PE ratio of Alkermes plc is 19.82 and the PB ratio is 2.58.